Anti‐CD20 monoclonal antibody therapy and minimal residual disease status of T‐cell/histiocyte‐rich large B cell non‐Hodgkin lymphoma

Valera, Elvis Terci; Queiróz, Rosane Gomes de Paula; Brassesco, María Sol; Scrideli, Carlos Alberto; Neves, Fábia Idalina; Tone, Luíz Gonzaga

doi:10.1002/pbc.23127

Cited by 2 publications

(2 citation statements)

References 6 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The matched-control analysis showed a trend toward a better response to chemotherapy for patients with DLBCL than T/HRBCL, whereas no difference was observed in OS between the two groups[11]. Recently, CHOP chemotherapy in combination with rituximab (R-CHOP) is used in T/HRBCL as it is used in all CD20 positive nodal and extranodal lymphomas[11,32]. Kim et al[33] reported that there was no significant difference in the CR rate to R-CHOP between T/HRBCL (91%) and DLBCL (97%).…”

Section: Discussionmentioning

confidence: 99%

Pancreatic T/histiocyte-rich large B-cell lymphoma: A case report and review of literature

Zheng

Zhou

Chen

et al. 2017

WJG

View full text Add to dashboard Cite

Primary pancreatic lymphoma (PPL) is an extremely rare form of extranodal malignant lymphoma. The most common histological subtype of PPL is diffuse large B cell lymphoma (DLBCL). In rare cases, PPL can also present as follicular lymphoma, small lymphocytic lymphoma, and T cell lymphoma either of non-Hodgkin’s lymphoma or of Hodgkin’s lymphoma. T-cell/histiocyte-rich large B-cell lymphoma (T/HRBCL) is an uncommon morphologic variant of DLBCL with aggressive clinical course, it is predominantly a nodal disease, but extranodal sites such as bone marrow, liver, and spleen can be involved. Pancreatic involvement of T/HRBCL was not presented before. Herein, we report a 48-year-old male who was hospitalized with complaints of jaundice, dark brown urine, pale stools, and nausea. The radiological evaluation revealed a pancreatic head mass and, following operative biopsy, the tumor was diagnosed as T/HRBCL. The patient achieved remission after six cycles of CHOP chemotherapy. Therefore, T/HRBCL can be treated similarly to the stage-matched DLBCL and both of them get equivalent outcomes after chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Pancreatic T/histiocyte-rich large B-cell lymphoma: A case report and review of literature

Zheng

Zhou

Chen

et al. 2017

WJG

View full text Add to dashboard Cite

show abstract

“…12 CHOP chemotherapy in combination with rituximab (R-CHOP) is used in T-cell/histiocyte-rich B-cell lymphoma (T/HRBCL) as it is used in all CD20 positive nodal and extranodal lymphomas. 16,17 Chemotherapy combined with radiotherapy may be useful for treatment. The role of surgery should be reserved for diagnostic or palliative intent.…”

Section: Discussionmentioning

confidence: 99%

Primary pancreatic lymphoma: diagnostic pitfall of an uncommon medical entity mimicking operable pancreatic carcinoma: case report and review of literature

et al. 2021

View full text Add to dashboard Cite

Almost all pancreatic neoplasms, including the commonest pancreatic ductal adenocarcinoma (PDAC) are derived from pancreatic epithelial components. Primary pancreatic lymphoma (PPL) is rare, accounting for less than 0.5% of all primary pancreatic tumours and presents a diagnostic and therapeutic challenge owing to their rarity, difficult access, and clinical and imaging features, which can mimic PDAC. A 26-year-old man presented with pain abdomen, jaundice, anorexia and weight loss for two months, along with two episodes of hematemesis and melena. Examination revealed an icteric patient with no palpable abdominal lump. His had a serum bilirubin of 13.6 mg/dl. His ultrasound abdomen, CT scan and MRCP showed a mass in the head and uncinate process of the pancreas with circumferential nodular thickening in second part of duodenum. Side viewing endoscopy was suggestive of carcinoma head of pancreas with duodenal infiltration, for which endoscopic biopsy was taken which revealed non-Hodgkin's lymphoma B cell type. A PET CT showed a metabolically active mass lesion in the head of pancreas, with no other focus of disease anywhere else, suggestive of primary pancreatic lymphoma. This patient was referred to Medical oncology and started on chemotherapy. Lymphoma should be considered when a large, homogeneous, hypoenhancing mass is encountered in the pancreatic head, and with bulky lymphadenopathy. Preoperative tissue diagnosis such as fine needle aspiration cytology with or without flow cytometry and/or laparoscopy/endoscopy guided tissue biopsy may be necessary. It is crucial to differentiate PPL from pancreatic adenocarcinoma since their treatment is primarily medical and prognosis differs considerably.

show abstract

Anti‐CD20 monoclonal antibody therapy and minimal residual disease status of T‐cell/histiocyte‐rich large B cell non‐Hodgkin lymphoma

Cited by 2 publications

References 6 publications

Pancreatic T/histiocyte-rich large B-cell lymphoma: A case report and review of literature

Pancreatic T/histiocyte-rich large B-cell lymphoma: A case report and review of literature

Primary pancreatic lymphoma: diagnostic pitfall of an uncommon medical entity mimicking operable pancreatic carcinoma: case report and review of literature

Contact Info

Product

Resources

About